NZ747350A - Methods for treating anemia - Google Patents
Methods for treating anemiaInfo
- Publication number
- NZ747350A NZ747350A NZ747350A NZ74735013A NZ747350A NZ 747350 A NZ747350 A NZ 747350A NZ 747350 A NZ747350 A NZ 747350A NZ 74735013 A NZ74735013 A NZ 74735013A NZ 747350 A NZ747350 A NZ 747350A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- treating anemia
- gdf
- treatment
- anemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718128P | 2012-10-24 | 2012-10-24 | |
| NZ743607A NZ743607A (en) | 2012-10-24 | 2013-10-23 | Methods for treating anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ747350A true NZ747350A (en) | 2020-07-31 |
Family
ID=50545463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ747350A NZ747350A (en) | 2012-10-24 | 2013-10-23 | Methods for treating anemia |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150266950A1 (enExample) |
| EP (2) | EP3527219A1 (enExample) |
| JP (3) | JP6401172B2 (enExample) |
| CN (3) | CN112933223A (enExample) |
| AU (4) | AU2013334660B2 (enExample) |
| CA (1) | CA2889286A1 (enExample) |
| HK (1) | HK1214504A1 (enExample) |
| NZ (1) | NZ747350A (enExample) |
| WO (1) | WO2014066487A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3045808C (en) | 2005-11-23 | 2022-08-16 | Acceleron Pharma, Inc. | Activin-actriia antagonists and uses for promoting bone growth |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| RU2473362C2 (ru) | 2007-02-01 | 2013-01-27 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
| TW201907946A (zh) | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| WO2008100384A2 (en) | 2007-02-09 | 2008-08-21 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| CN101861161B (zh) | 2007-09-18 | 2017-04-19 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| TW201919685A (zh) | 2008-08-14 | 2019-06-01 | 美商艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| CA2764890A1 (en) | 2009-06-08 | 2010-12-16 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
| CN104805105A (zh) | 2009-06-12 | 2015-07-29 | 阿塞勒隆制药公司 | 截短的actriib-fc融合蛋白 |
| EP2501400B1 (en) | 2009-11-17 | 2017-11-01 | Acceleron Pharma, Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| AU2011326586A1 (en) | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
| US20150266950A1 (en) * | 2012-10-24 | 2015-09-24 | Celgene Corporation | Methods for treating anemia |
| CA2890217C (en) | 2012-11-02 | 2021-07-20 | Yifu FANG | Activin-actrii antagonists and uses for treating bone and other disorders |
| WO2015143403A1 (en) * | 2014-03-21 | 2015-09-24 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11 |
| AP2017009674A0 (en) | 2014-06-13 | 2017-01-31 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| LT3227675T (lt) | 2014-12-03 | 2023-06-12 | Celgene Corporation | Aktivino actrii antagonistai ir naudojimas mielodisplastiniam sindromui gydyti |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| WO2016128523A1 (en) * | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| JP6976859B2 (ja) * | 2015-05-13 | 2021-12-08 | セルジーン コーポレイション | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
| EP4190805A3 (en) | 2015-05-20 | 2023-08-16 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| CA3031909A1 (en) | 2016-07-27 | 2018-02-01 | Acceleron Pharma Inc. | Methods and compositions for treating myelofibrosis |
| CN110461349B (zh) | 2016-11-10 | 2024-08-13 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| CN107011430B (zh) * | 2017-04-07 | 2020-09-01 | 哈尔滨医科大学 | 一种具有生物学活性的截短的生长分化因子11及其制备方法 |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CA3087008A1 (en) | 2018-01-12 | 2019-07-18 | Keros Therapeutics, Inc. | Activin receptor type iib variants and methods of use thereof |
| JP7405772B2 (ja) * | 2018-05-09 | 2023-12-26 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物 |
| WO2020257587A1 (en) * | 2019-06-19 | 2020-12-24 | Cornell University | Methods of promoting erythropoiesis and overcoming erythropoitein resistance in patients |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| CN113801880B (zh) * | 2021-07-27 | 2024-11-01 | 浙江大学 | 一种通过靶向敲除基因建立的早衰细胞模型及其sgRNA、构建方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| DE69534468T2 (de) * | 1994-07-08 | 2006-07-13 | The Johns Hopkins University School Of Medicine | Wachstums-differenzierungsfaktor-11 |
| US7795202B2 (en) | 1997-08-04 | 2010-09-14 | Neurorepair, Inc. | Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a) |
| JP2002526034A (ja) * | 1998-07-28 | 2002-08-20 | ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | 増殖分化因子−１１ |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| JP4429728B2 (ja) | 2002-02-21 | 2010-03-10 | ワイス エルエルシー | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| DK2332977T3 (en) | 2004-07-23 | 2016-02-29 | Acceleron Pharma Inc | ActRII receptor polypeptides |
| EP1863518A2 (en) * | 2005-03-30 | 2007-12-12 | Wyeth | Methods for stimulating hair growth by administering bmps |
| AU2006264339A1 (en) * | 2005-07-01 | 2007-01-11 | Acceleron Pharma Inc. | Lefty, Lefty derivatives and uses therof |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| MX373050B (es) | 2006-12-18 | 2020-05-21 | Acceleron Pharma Inc | Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojos. |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TW201907946A (zh) | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| WO2008109779A2 (en) | 2007-03-07 | 2008-09-12 | The Johns Hopkins University | Use of follistatin-like related gene (flrg) to increase muscle mass |
| CN101861161B (zh) | 2007-09-18 | 2017-04-19 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| KR20110031951A (ko) * | 2008-06-26 | 2011-03-29 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TW201919685A (zh) * | 2008-08-14 | 2019-06-01 | 美商艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| RU2642302C1 (ru) * | 2009-08-13 | 2018-01-24 | Акселерон Фарма Инк. | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| AU2011326586A1 (en) * | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
| US20150266950A1 (en) * | 2012-10-24 | 2015-09-24 | Celgene Corporation | Methods for treating anemia |
-
2013
- 2013-10-23 US US14/438,127 patent/US20150266950A1/en not_active Abandoned
- 2013-10-23 HK HK16102359.3A patent/HK1214504A1/zh unknown
- 2013-10-23 CN CN202011541918.9A patent/CN112933223A/zh active Pending
- 2013-10-23 NZ NZ747350A patent/NZ747350A/en unknown
- 2013-10-23 EP EP19151143.5A patent/EP3527219A1/en not_active Withdrawn
- 2013-10-23 WO PCT/US2013/066353 patent/WO2014066487A2/en not_active Ceased
- 2013-10-23 CA CA2889286A patent/CA2889286A1/en not_active Abandoned
- 2013-10-23 CN CN202011542063.1A patent/CN112957462A/zh active Pending
- 2013-10-23 EP EP13849960.3A patent/EP2911682A4/en not_active Withdrawn
- 2013-10-23 JP JP2015539751A patent/JP6401172B2/ja active Active
- 2013-10-23 CN CN201380067832.9A patent/CN104981250A/zh active Pending
- 2013-10-23 AU AU2013334660A patent/AU2013334660B2/en active Active
-
2018
- 2018-07-12 JP JP2018131952A patent/JP2018184430A/ja active Pending
- 2018-11-02 AU AU2018256635A patent/AU2018256635A1/en not_active Abandoned
-
2020
- 2020-05-15 AU AU2020203198A patent/AU2020203198B2/en active Active
- 2020-06-24 JP JP2020108654A patent/JP2020183390A/ja not_active Withdrawn
-
2022
- 2022-03-21 AU AU2022201923A patent/AU2022201923A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN112957462A (zh) | 2021-06-15 |
| HK1214504A1 (zh) | 2016-07-29 |
| JP6401172B2 (ja) | 2018-10-10 |
| AU2013334660B2 (en) | 2018-08-09 |
| CA2889286A1 (en) | 2014-05-01 |
| AU2020203198B2 (en) | 2021-12-23 |
| CN104981250A (zh) | 2015-10-14 |
| JP2020183390A (ja) | 2020-11-12 |
| AU2018256635A1 (en) | 2018-11-22 |
| CN112933223A (zh) | 2021-06-11 |
| WO2014066487A3 (en) | 2014-06-19 |
| JP2018184430A (ja) | 2018-11-22 |
| EP2911682A4 (en) | 2016-03-23 |
| EP3527219A1 (en) | 2019-08-21 |
| AU2020203198A1 (en) | 2020-06-11 |
| AU2013334660A1 (en) | 2015-05-14 |
| EP2911682A2 (en) | 2015-09-02 |
| WO2014066487A2 (en) | 2014-05-01 |
| US20150266950A1 (en) | 2015-09-24 |
| JP2016503398A (ja) | 2016-02-04 |
| AU2022201923A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ747350A (en) | Methods for treating anemia | |
| IL276405B (en) | Monoclonal antibodies to factor 15 (gdf-15) for growth and differentiation, and their use for the treatment of cancerous tumors and cancer | |
| NZ706189A (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) | |
| MY183712A (en) | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases | |
| SG10201804306VA (en) | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | |
| MY183637A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| MX2024008826A (es) | Composicion para la estimulacion ovarica controlada. | |
| MY193524A (en) | Diaryl macrocycles as modulators of protein kinases | |
| NZ748345A (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
| SG10201908388UA (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| MY191087A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| MX2015011509A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
| MX2015006859A (es) | Anticuerpos anti-vegf y sus usos. | |
| TN2014000409A1 (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
| MX2014010537A (es) | Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas. | |
| MX2015008944A (es) | Proceso de liofilizacion. | |
| MX2016006544A (es) | Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas. | |
| GB2524553C (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia | |
| NZ743607A (en) | Methods for treating anemia | |
| GB2524552B (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 OCT 2022 BY CPA GLOBAL Effective date: 20210909 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 OCT 2023 BY CPA GLOBAL Effective date: 20220909 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 OCT 2024 BY CPA GLOBAL Effective date: 20230907 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240905 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250911 |